Senores Pharmaceuticals Limited
Senores Pharmaceuticals promoters and promoter group confirmed no new encumbrances on company shares during the financial year ended March 31, 2026. This annual disclosure ensures compliance with SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.
Apr 22 2026 17:04:00
Senores Pharmaceuticals Limited
Senores Pharmaceuticals issued 11.7 lakh convertible equity warrants via a preferential issue on March 28, 2026, to promoter and promoter group members. The company also appointed Jatin Gajjar as CTO and noted the resignation of President R&D Manohar Lalge.
Apr 07 2026 17:04:00
Senores Pharmaceuticals Limited
Senores Pharmaceuticals, Inc. (SPI), a subsidiary of Senores Pharmaceuticals Limited, has formed a strategic joint venture named Amerisyn, LLC, in the United States. This JV will supply high-quality pharmaceutical products to the U.S. Federal Government and defense sector, marking a significant entry into a high-entry-barrier market.
Apr 03 2026 20:04:00
Senores Pharmaceuticals Ltd - 544319 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Senores Pharmaceuticals announced a strategic joint venture, Amerisyn, LLC, in the United States. This JV will target U.S. Federal and Defense sector supplies, marking a key entry into government procurement.
Apr 03 2026 20:04:00
Senores Pharmaceuticals Limited
Senores Pharmaceuticals' wholly owned subsidiary, Senores Pharmaceuticals Inc., acquired a 70% membership interest in Amerisyn, LLC. This strategic acquisition establishes Amerisyn, LLC, a pharmaceuticals company incorporated on March 5, 2026, as a step-down subsidiary in the USA, expanding the company's global footprint.
Apr 03 2026 19:04:00
Senores Pharmaceuticals Limited
Senores Pharmaceuticals' wholly owned subsidiary, Senores Pharmaceuticals, Inc., USA, formed a joint venture named Amerisyn, LLC. The subsidiary subscribed to a 70% membership interest, making Amerisyn a step-down subsidiary focused on pharmaceuticals in North Carolina.
Apr 03 2026 19:04:00
Senores Pharmaceuticals Limited
Senores Pharmaceuticals' promoter and promoter group received an allotment of 11.7 lakh convertible equity warrants on a preferential basis. This allotment increases their diluted shareholding to 47.16% of the company's total diluted share capital.
Apr 02 2026 18:04:00
Senores Pharmaceuticals Limited
Senores Pharmaceuticals' promoter and promoter group received an allotment of 11.7 lakh convertible equity warrants on a preferential basis. This allotment increases their diluted shareholding to 47.16% of the company's total diluted share capital.
Apr 02 2026 18:04:00
Senores Pharmaceuticals Limited
Senores Pharmaceuticals' promoter and promoter group received an allotment of 11.7 lakh convertible equity warrants on a preferential basis. This allotment increases their diluted shareholding to 47.16% of the company's total diluted share capital.
Apr 02 2026 18:04:00
Senores Pharmaceuticals Limited
Senores Pharmaceuticals' promoter and promoter group received an allotment of 11.7 lakh convertible equity warrants on a preferential basis. This allotment increases their diluted shareholding to 47.16% of the company's total diluted share capital.
Apr 02 2026 18:04:00
Read More
